Sonnet BioTherapeutics Holdings, Inc. SONN shares are trading lower by 27.6% to $1.31 Wednesday morning after the company announced the pricing of a public offering involving 2,843,750 shares of common stock or pre-funded warrants, along with investor warrants allowing the purchase of up to 5,687,500 shares of common stock.
What Else?
Sonnet BioTherapeutics says the combined offering price is $1.60 per share, totaling approximately $4.55 million in gross proceeds before expenses. Each investor warrant is exercisable for one share of common stock at $1.60 per share over five years.
The offering is set to close around October 27, 2023, and is led by existing investors, with Chardan and Ladenburg Thalmann & Co. Inc. serving as joint book-running managers.
Sonnet BioTherapeutics says the funds raised will be utilized for research and development, including clinical trials, as well as general corporate purposes.
See Also: Why Alphatec (ATEC) Stock Is Nosediving
According to data from Benzinga Pro, Sonnet BioTherapeutics has a 52-week high of $65.93 and a 52-week low of $1.10.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
